Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Biotechnology
Health
Pharmaceutical
Clinical Trials
Oncology
Ono Pharmaceutical

More Like This

Business Wire logo

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

Business Wire logo

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Business Wire logo

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

Business Wire logo

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Business Wire logo

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Business Wire logo

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Business Wire logo

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Business Wire logo

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us